Business
Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
— Successfully demonstrates strong tolerability, sustained drug release and safety S...
About this update from Silo Wellness Inc
[{"type":"text","content":"Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study \n\n\n\n\n — Successfully demonstrates strong tolerability, sustained drug release and safety\n \n\n\n SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced positive results for its preclinical study evaluating SP-26, a novel extended-release ketamine implant which it believes supports SP-26’s potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia.\n \n\n All study endpoints were met, including survival, clinical observations, body weight stability, neurological assessments, and histopathological evaluation.\n \n\n “Our team is pleased to report that SP-26 met all expectations in this preclinical study,” said Eric Weisblum, CEO of Silo Pharma. “We believe these results support the advancement of SP-26 as a next-generation therapeutic for fibromyalgia, combining the proven efficacy of ketamine with the safety and convenience of extended-release delivery.”\n \n\n The study, which was conducted in minipigs, evaluated the pharmacokinetics, safety, and local tolerability of SP-26 formulations when administered subcutaneously. SP-26 implants are designed to deliver ketamine at a controlled rate, avoiding the dissociative effects associated with IV bolus injection and providing a viable alternative to highly addictive opioid treatments. The preclinical results position Silo to advance toward clinical studies and expand the Company’s pipeline for chronic pain and mental health indications.\n \n\n Study Highlights:\n \n\n •     Safety Profile: No implant-related adverse events were observed. Animals maintained a healthy weight, normal neurological behavior, and full survival to study conclusion.\n \n •    Sustained Drug Release: Ketamine was steadily released post-implantation, with measurable systemic exposure achieved across all dose levels. Peak drug levels were reached within 1 hour in most subjects, with sustained plasma concentrations observed for up to 22 days.\n \n •    Minimal Tissue Reactio...